Pricing Log in Create free account

Definium Therapeutics, Inc. (DFTX) vs Xenon Pharmaceuticals Inc. (XENE)

Definium Therapeutics, Inc. and Xenon Pharmaceuticals Inc. are both Biotechnology companies. Definium Therapeutics, Inc. is the larger, with a market value of $4.1B against $3.7B — 1.1× the size. Across the 11 metrics below, Xenon Pharmaceuticals Inc. leads on 7 and Definium Therapeutics, Inc. on 4.

Valuation

Metric DFTX XENE Biotechnology median
P/E n/m n/m 10.60
P/S n/m 229.41 9.40
P/B 4.01 3.13 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 176.02 9.02
Earnings yield (10.31%) (12.15%) (32.88%)
Free cash flow yield (4.56%) (8.71%) (23.13%)

Profitability

Metric DFTX XENE Biotechnology median
Gross margin 0.00% 28.40% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (64.09%) (43.62%) (51.96%)
Return on assets (51.35%) (41.54%) (46.06%)
Return on invested capital 0.00% (88.54%) 0.00%

Growth

Metric DFTX XENE Biotechnology median
Revenue growth (TTM) — (8.15%) 6.76%
EPS growth (last fiscal year) (33.77%) (44.85%) 29.88%
Revenue growth, 5-year CAGR — 89.00% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DFTX XENE Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 6.95 21.02 4.97
Net debt to EBITDA 2.21 1.48 1.01

Dividend

Metric DFTX XENE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DFTX XENE Biotechnology median
Market cap 4.08b 3.65b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack